MétaCan
Menu
Back to cohort
Record W4386187511 · doi:10.1093/cid/ciad506

Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes

2023· article· en· W4386187511 on OpenAlexfundno aff
Marion G. Peters, Man‐Fung Yuen, Norah A. Terrault, John Fry, Pietro Lampertico, Ed Gane, Carey Hwang, Luisa M. Stamm, Mitchell Leus, Mala K. Maini, Patricia Méndez, Isabelle Lonjon‐Domanec, Thomas Berg, Su Wang, Poonam Mishra, Eric Donaldson, Stephanie Buchholz, Veronica Miller, Oliver Lenz

Bibliographic record

VenueClinical Infectious Diseases · 2023
Typearticle
Languageen
FieldMedicine
TopicHepatitis B Virus Studies
Canadian institutionsnot available
FundersHouston Methodist Research InstituteMerck Sharp and DohmeGenentechNational Institutes of HealthNorgineSwedish Orphan BiovitrumEuropean Association for the Study of the LiverEisaiSirtex MedicalArrowhead PharmaceuticalsUniversity College LondonSysmex CorporationCanadian Association for the Study of the LiverAlnylam PharmaceuticalsVir BiotechnologySilverback TherapeuticsShionogiIpsenBundesinstitut für Arzneimittel und MedizinprodukteAbbott LaboratoriesQuest DiagnosticsUniversità degli Studi di MilanoGilead SciencesAmerican Association for the Study of Liver DiseasesF. Hoffmann-La RocheAlexion PharmaceuticalsRocheGlaxoSmithKlineFalk FoundationBristol-Myers Squibb
KeywordsViewpointsMedicineChronic hepatitisHepatitis BHepatitis B virusClinical trialFamily medicineIntensive care medicineClinical researchInternal medicineVirologyVirus

Abstract

fetched live from OpenAlex

Chronic hepatitis B, a major cause of liver disease and cancer, affects >250 million people worldwide. Currently there is no cure, only suppressive therapies. Efforts to develop finite curative hepatitis B virus (HBV) therapies are underway, consisting of combinations of multiple novel agents with or without nucleos(t)ide reverse-transcriptase inhibitors. The HBV Forum convened a webinar in July 2021, along with subsequent working group discussions to address how and when to stop finite therapy for demonstration of sustained off-treatment efficacy and safety responses. Participants included leading experts in academia, clinical practice, pharmaceutical companies, patient representatives, and regulatory agencies. This Viewpoints article outlines areas of consensus within our multistakeholder group for stopping finite therapies in chronic hepatitis B investigational studies, including trial design, patient selection, outcomes, biomarkers, predefined stopping criteria, predefined retreatment criteria, duration of investigational therapies, and follow-up after stopping therapy. Future research of unmet needs are discussed.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.058
metaresearch head score (Gemma)0.090
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.058
Threshold uncertainty score0.305

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0580.090
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0010.001
Science and technology studies0.0010.005
Scholarly communication0.0050.006
Open science0.0010.002
Research integrity0.0050.008
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.056
GPT teacher head0.366
Teacher spread0.309 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations8
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueClinical Infectious DiseasesSame topicHepatitis B Virus StudiesFrench-language works237,207